founding-member-of-QUTAC
Quantum Computing: Boehringer Ingelheim is a Founding Member of QUTACTen leading German companies form this newly created Quantum Technology and Application ConsortiumTogether, the members want to explore industrial applications for quantum computingQuantum computing has also great potential for pharmaceutical research and development (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 9, 2021 Category: Research Source Type: news

Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaksLifebit ’s deep learning, Natural Language Processing and Artificial Intelligence platform automatically detects and tracks global infectious disease outbreaks using real-world evidenceThe captured insights can accelerate detection of the latest outbreaks including transboundary diseases and emerging pathogens (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 2, 2021 Category: Research Source Type: news

Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH  FDA ’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfill the unmet medical needs of people affected by NASH.Boehringer Ingelheim ’s focus on the development of next generation NASH treatments builds on its strong track record of bringing new therapies to people with cardiometabolic diseases. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 2, 2021 Category: Research Source Type: news

BTD for GlyT1 in Schizophrenia
Boehringer Ingelheim ’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy DesignationBI 425809, a novel glycine transporter-1 (Gly-T1) inhibitor to be Studied in First-of-its-Kind Phase III Trials, Incorporating Speech Analytics and Virtual Reality Functional Capacity Assessments. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 24, 2021 Category: Research Source Type: news

emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for Jardiance ® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fractionThe positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk of cardiovascular death or hospitalization for heart failure  The results were observed in adults with heart failure with reduced ejection fraction (HFrEF), with or without diabetesJardiance is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 21, 2021 Category: Research Source Type: news

collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 10, 2021 Category: Research Source Type: news

Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolioBoehringer Ingelheim continues to stay at the forefront of innovation and provide producers with the right tools for disease preventionThe Company ’s Ubroseal® Blue brings confidence of best practice when it comes to sealant administration and removal (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 14, 2021 Category: Research Source Type: news

expanded-collaboration-MD-Anderson
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer  Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center (VRDC)  The continued collaboration will explore lung cancer targeting KRAS and TRAILR2 molecules from Boehringer Ingelheim ’s growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancer  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 14, 2021 Category: Research Source Type: news

Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and ObesityNew studies mark an important advancement of Boehringer Ingelheim ’s cardiometabolic focus areas obesity and NASH.The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management and NASH improvementThe Phase 2 trials for BI 456906 in obesity and NASH are part of the long-term collaboration between Boehringer Ingelheim and Zealand Pharma, with a prior Phase 2 trial of BI 456906 in people with type 2 diabetes initiated in 2020.   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 13, 2021 Category: Research Source Type: news

PREVEXXION ® RN: Marek’s disease vaccine available in EU UK
PREVEXXION ® RN: the next generation of Marek’s disease vaccines now available in the EU and the UKPREVEXXION ® RN is the results of unprecedented engineering design in vaccinology which brings optimal safety and efficacy balanceThe product ’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most virulent Marek’s disease virus strainsIt is also fully compatible with VAXXITEK ® HVT+IBD and available in the same ampoule for added convenience (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 8, 2021 Category: Research Source Type: news

2020-Positive-business-momentum-despite-COVID-19-impact
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19  Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus  Overall R&D investment up 7% to 3.7 billion EUR in 2020 (18.9% of net sales)  Outlook 2021: slight year-on-year increase in net sales on a comparable basis   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 23, 2021 Category: Research Source Type: news

collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric DisordersThrough the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia.  The new collaboration further expands Boehringer Ingelheim ’s circuitry-based approach to precision psychiatry and solidifies the company’s commitment to provide better treatments for patients li...
Source: Boehringer Ingelheim Corporate News - March 16, 2021 Category: Research Source Type: news

Stop of treatment in COVID-19 study
Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19Phase II study assessing BI 764198, a novel first-in-class compound, for patients hospitalized with COVID-19 with respiratory complications discontinued due to lack of efficacy in this indicationBoehringer Ingelheim remains committed to other research and development efforts in COVID-19 including new SARS-CoV-2 neutralizing antibodies (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 12, 2021 Category: Research Source Type: news

Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra Join Forces to Identify and  Validate Innovative Peptides for the Treatment of ObesityThe research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra and expands Boehringer Ingelheim ’s research into approaches with first in class potential for the treatment of obesity Obesity is a complex cardiometabolic disease with growing global prevalence and limited treatment options that are not sufficiently effective or are associated with adverse events (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 1, 2021 Category: Research Source Type: news

ATM-Ranking-2021
Access-To-Medicine: Ranking Progress and Focus on Early-Phase R&DBoehringer Ingelheim climbs two more places to rank 12 in 2021  Access-To-Medicine Index ​New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected in index criteriaWide range of projects addressing health challenges in low- and middle-income countries recognized (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 26, 2021 Category: Research Source Type: news

global-top-employer
Award: Boehringer Ingelheim is Global Top Employer 2021 Boehringer Ingelheim is one of sixteen top employers worldwide Awards in 27 countries and in Europe and the Latin America and Asia-Pacific regions Boehringer Ingelheim performs particularly well in strategy, corporate culture and employee involvement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 21, 2021 Category: Research Source Type: news

Boehringer Ingelheim partners with PetMedix
Boehringer Ingelheim has entered into a partnership with PetMedix, a UK based research and development stage biopharmaceutical company.Strengthening partnerships to accelerate innovation and growth is now one of the key elements of Boehringer Ingelheim ’s refocused strategy. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim receives EMA marketing authorization  for NexGard® COMBO, the first isoxazoline-based full endectocide for catsThe product features a triple action formula that includes esafoxolaner – the newly developed form of afoxolaner - combined with eprinomectin and praziquantel.This innovative broad spectrum topical parasiticide is easy and convenient for cat owners.It kills a wider range of parasites than any other product on the market, covering core external parasites like fleas and ticks as well as internal parasites, including tapeworms. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies  Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancersLatest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim ’s position in the cancer vaccine and T-cell engager spacesAgreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio ’s  EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic a...
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

Partnering-with-google-in-quantum-computing
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D  Quantum computing offers the potential to significantly accelerate and optimize the discovery of future new medicines for patientsScientists from both companies will be breaking new ground in the application of quantum computing to molecular dynamics simulationsBoehringer Ingelheim has set up a dedicated Quantum Lab with leading experts  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 9, 2021 Category: Research Source Type: news

Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol ® IleitisThe Paul Ehrlich Institute (PEI) accepted new language on the label of Enterisol ® Ileitis, the only global oral live Lawsonia intracellularis vaccine to control Ileitis in swine.Boehringer Ingelheim strives to continuously bring innovation to the market to improve animal health. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 21, 2020 Category: Research Source Type: news

SARS-CoV-2-Neutralizing-Antibody-enters-Clinical-Phase
New SARS-CoV-2 Neutralizing Antibody enters Clinical PhaseCologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and preventionBI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus neutralizing properties in pre-clinical researchPhase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 18, 2020 Category: Research Source Type: news

Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates  Acquisition will add another key dimension to Boehringer Ingelheim ’s focus on patients with difficult-to-treat solid tumors NBE-Therapeutics ’ pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform NBE-Therapeutics ’ will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 10, 2020 Category: Research Source Type: news

Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to Acquire Labor Dr. Merk& Kollegen to Strengthen its Next Generation Cancer Immunology ProgramBoehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech company Labor Dr. Merk& KollegenTransaction expands Boehringer Ingelheim ’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatmentsBoehringer Ingelheim aims to accelerate the delivery of first-in-class immuno-oncology therapies to patients around the world   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 9, 2020 Category: Research Source Type: news

Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health.The International Poultry Council represents a unified and harmonized voice of the poultry industry. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 7, 2020 Category: Research Source Type: news

collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer  New collaboration strengthens Boehringer Ingelheim ’s cancer research strategy to develop novel treatment options for patients with lung or gastrointestinal cancersProxygen ’s unique molecular glue degrader discovery platform complements Boehringer Ingelheim’s focus on proteolysis targeting chimeras (PROTACs) in the aim of degrading cancer drivers that were previously considered undruggable  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 7, 2020 Category: Research Source Type: news

bix_facilitates_global_partnerships
Boehringer Ingelheim: Digital Lab BI X Facilitates Global PartnershipsPartnerships play an essential role for BI X in creating digitally innovative products and services to accelerate the development of better healthcare for humans and animalsAmong other topics, BI X is searching for partners in the areas of complex neurological rehabilitation and single-cell multimodal omics technologiesSecond hub in Shanghai and new partnership platform to provide more cooperation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 30, 2020 Category: Research Source Type: news

empa-reg-outcome-recurrent-events
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME ® trialIn new results published in The Lancet Diabetes& Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular diseaseRecurrent cardiovascular events in people with type 2 diabetes are responsible for considerable clinical and s...
Source: Boehringer Ingelheim Corporate News - November 18, 2020 Category: Research Source Type: news

Positive-CHMP-opinion-for-dabigatran-in-children
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa ® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of ageNo approved therapy for the treatment and prevention of venous thromboembolic events in children until nowCurrent standard of care often associated with frequent monitoring of anticoagulation or daily injections1Positive opinion is based on a dedicated clinical pediatric program for dabigatran, including the DIVERSITY study,2 which supplements dabigatran ´s established and well-documented safety and effic...
Source: Boehringer Ingelheim Corporate News - November 13, 2020 Category: Research Source Type: news

new_analysis_nintedanib_SSc_ILD
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1Interim analysis demonstrated long-term safety and suggested a sustained effect of nintedanib on slowing lung function decline in patients with SSc-ILD1  Safety and efficacy profile of nintedanib was consistent with the Phase III SENSCIS ® trial, according to this analysis1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2020 Category: Research Source Type: news

Developing-potential-treatment-for-severe-COVID
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available.This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,1 potentially reducing the need for mechanical ventilation and potentially saving lives.The initiation of this Phase 2 tri...
Source: Boehringer Ingelheim Corporate News - October 28, 2020 Category: Research Source Type: news

Developing-potential-treatment-for-severe-COVID19-complications
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available.This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,1 potentially reducing the need for mechanical ventilation and potentially saving lives.The initiation of this Phase 2 tri...
Source: Boehringer Ingelheim Corporate News - October 28, 2020 Category: Research Source Type: news

Boehringer Ingelheim Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigsThis novel device will bring benefits to swine producers ensuring improved safety and efficacy of vaccinationForming new partnerships is fully aligned with part of Boehringer Ingelheim ’s animal health strategy, aiming to accelerate innovation and growth (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 23, 2020 Category: Research Source Type: news

Purevax range now available in 0.5 ml presentation
Purevax ® range now available in 0.5 ml presentationBoehringer Ingelheim announces reduced volume vaccines for catsMore convenient vaccination experience combined with same efficacyPurevax ® is the only fully adjuvant‑free feline vaccine range (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 14, 2020 Category: Research Source Type: news

Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the ClinicThe collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim ’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford BioTherapeutics’ proprietary OGAP® (Oxford Genome Anatomy Project) target discovery platform, is the latest in a series of collaborations that strengthens Boehringer Ingelheim’s position and leading asse ts in cancer immunology.  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 14, 2020 Category: Research Source Type: news

Advance study shows vaccinating results in increased milk production
New ADVANCE study shows vaccinating results in increased milk productionThe ADVANCE1 study demonstrates benefits of vaccinationBoehringer Ingelheim remains committed to bringing new findings to its customers through continuous research (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 5, 2020 Category: Research Source Type: news

Winners of the 2020 European PRRS Research Award
announcedBoehringer Ingelheim recognizes scientific excellence by awarding three research proposals with a funding of 25,000 euro eachThe company sponsored the annual European PRRS Awards for the seventh time (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 1, 2020 Category: Research Source Type: news

Boehringer Ingelheim and Fraunhofer partnership
Boehringer Ingelheim and Fraunhofer IME launch collaborationThis partnership aims to develop sustainable animal health productsBoehringer Ingelheim continues to strive to minimize the environmental footprint of its operations and products (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 30, 2020 Category: Research Source Type: news

Partnership to further develop pet market in China
Boehringer  Ingelheim invests to further develop the pet care market in ChinaBoehringer  Ingelheim has acquired an equity stake in New Ruipeng Group (NRP Group) which operates digital and clinical pet services across China The  partnership with NRP Group aims to expand health solutions, quality advice and professional care to the growing number of pets and pet owners in China  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 29, 2020 Category: Research Source Type: news

World Rabies Day 2020 sustainable dog vaccination
Boehringer Ingelheim steps up its efforts to eliminate rabies through sustainable programs  Vaccinating dogs most effective to protect human lives  Boehringer Ingelheim supports local self-sustaining programs that fight rabies  Contributing to continuous rabies awareness and vaccination campaigns key to the company ’s strategy  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 28, 2020 Category: Research Source Type: news

clinical_collaboration_with_Mirati
BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR  First clinical study to evaluate novel combination blocking KRAS G12C and its activator SOS1 to potentially increase the therapeutic benefit for lung and colorectal cancer patientsStudy is based on preclinical evidence suggesting synergistic effect of KRAS G12C and SOS1 inhibition (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 17, 2020 Category: Research Source Type: news

digital_leader_award_2020
Successful IT transformation recognized: Boehringer Ingelheim wins Digital Leader Award 2020Award values strategic contribution of the IT organization to the innovative strength of the pharmaceutical companyTransformation drives company-wide digital innovationEarly investments in digital technologies have been crucial to maintain business operations under COVID-19     (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2020 Category: Research Source Type: news

Phase II results cognitive impairment schizophrenia
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophreniaResults presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has met its primary endpoint1,2Trial results, together with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, add to the body of evidence for Boehringer Ingelheim ’s schizophrenia research program3Cognitive impairment associated with schizophrenia (CIAS) has a significant negative impact on daily functioning and remains a focus for Boehringer I...
Source: Boehringer Ingelheim Corporate News - September 14, 2020 Category: Research Source Type: news

Partnership-with-clicktherapeutics
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia This collaboration combines Click Therapeutics ’ specialty in developing efficacious and engaging digital therapeutics with Boehringer Ingelheim’s expertise in clinical development of treatments for neuropsychiatric diseases, furthering Boehringer Ingelheim’s commitment to exploring digital innovations to benefit patients with unmet medica l needsTogether the companies will develop and commercialize a prescription-b...
Source: Boehringer Ingelheim Corporate News - September 11, 2020 Category: Research Source Type: news

Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal CancersFirst-in-class bi-specific antibody BI 905711 activates a pathway in TRAILR2 and CDH17 co-expressing tumor cells that leads to their destructionMay result in a more tolerable and selective therapy for patients affected with gastrointestinal cancers by avoiding liver toxicity commonly observed in other therapy approaches targeting TRAILR2Adds a promising candidate to Boehringer Ingelheim ’s multipronged oncology portfolio that combines cancer cell-directed and cancer immunol...
Source: Boehringer Ingelheim Corporate News - September 10, 2020 Category: Research Source Type: news

discontinuation-bi-1467335-diabetic-retinopathy
Boehringer Ingelheim discontinues development of BI 1467335 for Diabetic RetinopathyBI 1467335 was acquired from Pharmaxis in 2015 as part of Boehringer Ingelheim ’s growing Retinal Health R&D pipeline portfolioBoehringer Ingelheim has terminated the agreement with Pharmaxis with 90 days ’ notice during which time Pharmaxis can request return of all existing data and intellectual property.Boehringer Ingelheim will continue to advance its comprehensive portfolio of next generation retinal therapy approachesPharmaxis will continue its development of small molecule amine oxidase inhibitors with a phase 2 study...
Source: Boehringer Ingelheim Corporate News - September 7, 2020 Category: Research Source Type: news

GioTag Final Data
Conclusions from the observational GioTag study were   published in Future OncologyiGiotrif/Gilotrif (afatinib) followed by osimertinib showed median overall survival (OS) of 37.6 months in patients with EGFR mutation-positive NSCLC (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 2, 2020 Category: Research Source Type: news

Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 27, 2020 Category: Research Source Type: news

Launch-of-CARE-Consortium
Europe ’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus ThreatsCARE (Corona Accelerated R&D in Europe), supported by Europe ’s Innovative Medicines Initiative (IMI), is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment options for COVID-19The initiative is committed to a long-term understanding of the disease and development of therapies for COVID-19 and future coronavirus threats in addition to urgent efforts to repurpose existing therapies as potential immediate response.The CARE consortium will acceler...
Source: Boehringer Ingelheim Corporate News - August 18, 2020 Category: Research Source Type: news

biolabs-heidelberg
Boehringer Ingelheim Supports BioLabs First European Location BioLabs Heidelberg with Founding Sponsorship   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 17, 2020 Category: Research Source Type: news